ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas2026
MMP9 regulates osteogenesis and MMP2 expression through the TGF-β1/SMAD2/3 signaling pathway in lipopolysaccharide-induced osteoblasts.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinases (MMP) act as effectors and regulators in normal growth and development as well as in pathological processes. The gelatinases MMP2 and MMP9 exhibit similar structures and biological reactions. The purpose of this study was to clarify the relationship between MMP9 and MMP2 in lipopolysaccharide (LPS)-induced osteoblasts. MC3T3-E1 cells were pretreated with or without TGF-β1 inhibitor (20 nM) and SMAD2/3 inhibitor (20 nM) for 1 h, and then with pcDNA3.1-mMMP9 (0.8 μg/mL) for 48 h. Quantitative real-time PCR, western blot, and immunocytochemistry were performed to detect MMP2, TGF-β1, and/or SMAD2/3 expression. Luciferase reporter assay and electrophoretic mobility shift assay (EMSA) were performed to examine the regulatory effect of SMAD2/3 on MMP2 gene transcription. RUNX2, OSX, ALP, type I collagen, and OCN expression was detected in LPS (20 μg/mL)-stimulated MC3T3-E1 cells after MMP9 treatment. MMP9 activated the expression of TGF-β1 and phosphorylation of SMAD2/3. Phosphorylated SMAD2/3 translocalized into nuclei to bind to SMAD-binding elements in the promoter of the MMP2 gene, inhibiting MMP2 gene transcription. Additionally, MMP9 increased RUNX2, OSX, ALP, COL I, and OCN expression in LPS-induced MC3T3 cells. MMP9 may regulate osteogenesis through TGF-β1-SMAD2/3/-MMP2 signaling during the inflammation process.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.